Fauci Out Selling Early Oral Treatments Now—Seeking to Monetize the Majority of COVID-19 Cases

Fauci Out Selling Early Oral Treatments Now—Seeking to Monetize the Majority of COVID-19 Cases

Dr. Anthony Fauci is back in sales mode, now representing his pharmaceutical patrons. After spending many billions already on what in many cases have become throw-away monoclonal antibodies and several questionable therapies in the pipeline, the head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to POTUS spent lots of time minimizing the mounting evidence associated with many generic early COVID-19 treatment options, from fluvoxamine and ivermectin to even hydroxychloroquine used in select scenarios. Now Fauci will deliver to the market the perfect pill and help the industry monetize the massive market for early-onset COVID-19 mild-to-moderate cases—the 90%+ of total cases that fit in that category.

Reuters recently showcased some of Fauci’s latest pitches, including the ability to care for individuals early, stopping the virus from progressing to an upper airway infection, thus turning the virus into what is more like a common cold. 

Fauci suggests his perfect pill—one that blocks a specific viral function, is taken once a day and is low in toxicity with minimal drug-drug interactions. It is orally administered and ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee